JULY 17, 2026 AT 08:34 AM

GSK (GSK LN) discontinues camlipixant development in refractory chronic cough after CALM-2 did not reach statistical significance in the primary endpoint

Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.

Open Dashboard

#UNITED KINGDOM#EUROPE#GLAXOSMITHKLINE PLC#GSK.LN#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FTSE 100 INDEX#GSK PLC#GSK#FTSE 100

External